{"title":"2018年中重度IBD患者的革命性疗法","authors":"A. Ertan","doi":"10.24966/ghr-2566/100023","DOIUrl":null,"url":null,"abstract":"There has been great progress towards the development of new agents for the treatment of Inflammatory Bowel Disease (IBD). New therapeutic avenues have become possible, including the development of agents that target specific genetic pathways found to be relevant in patients with IBD. Moderate-to-severe IBD patients have required an infusion or subcutaneous injection therapies in the past, but there is an influx of new oral medications in development and a promising one is already approved by the FDA, tofacitinib. We will summarize this progress in this editorial.","PeriodicalId":92206,"journal":{"name":"HSOA journal of gastroenterology & hepatology research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Revolutionary Therapies in Patients with Moderate-to-Severe IBD in 2018\",\"authors\":\"A. Ertan\",\"doi\":\"10.24966/ghr-2566/100023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There has been great progress towards the development of new agents for the treatment of Inflammatory Bowel Disease (IBD). New therapeutic avenues have become possible, including the development of agents that target specific genetic pathways found to be relevant in patients with IBD. Moderate-to-severe IBD patients have required an infusion or subcutaneous injection therapies in the past, but there is an influx of new oral medications in development and a promising one is already approved by the FDA, tofacitinib. We will summarize this progress in this editorial.\",\"PeriodicalId\":92206,\"journal\":{\"name\":\"HSOA journal of gastroenterology & hepatology research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HSOA journal of gastroenterology & hepatology research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24966/ghr-2566/100023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HSOA journal of gastroenterology & hepatology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24966/ghr-2566/100023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Revolutionary Therapies in Patients with Moderate-to-Severe IBD in 2018
There has been great progress towards the development of new agents for the treatment of Inflammatory Bowel Disease (IBD). New therapeutic avenues have become possible, including the development of agents that target specific genetic pathways found to be relevant in patients with IBD. Moderate-to-severe IBD patients have required an infusion or subcutaneous injection therapies in the past, but there is an influx of new oral medications in development and a promising one is already approved by the FDA, tofacitinib. We will summarize this progress in this editorial.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
